Investor's Business Daily on MSN18h
After Eli Lilly's 7% Slump On Its Guidance Cut, What's Left To Like? A Lot, Says One Analyst.
There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.
Pennsylvania woman speaks out after Independence Blue Cross drops weight loss drug coverage
A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.
Eli Lilly cuts Q4 sales forecast, but analyst remains bullish on stock—here’s why
Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...